20例阿尔茨海默病患者从莱卡耐单抗切换到多纳耐单抗的安全性

IF 3.4 3区医学 Q2 NEUROSCIENCES

Journal of Alzheimer's Disease Pub Date : 2025-07-24 DOI:10.1177/13872877251361051

Heii Arai, Satoko Aiba, Reiko Arai

{"title":"20例阿尔茨海默病患者从莱卡耐单抗切换到多纳耐单抗的安全性","authors":"Heii Arai, Satoko Aiba, Reiko Arai","doi":"10.1177/13872877251361051","DOIUrl":null,"url":null,"abstract":"We retrospectively reviewed 20 consecutive patients with Alzheimer's disease who switched from lecanemab to donanemab. No new amyloid-related imaging abnormalities (ARIA) or significant adverse events were observed during the first five donanemab infusions. Prior exposure to lecanemab may reduce ARIA risk. Cognitive function remained stable. These preliminary observations suggest that switching between anti-amyloid therapies may be safe in the short term, though larger prospective studies are warranted.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251361051"},"PeriodicalIF":3.4000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease.\",\"authors\":\"Heii Arai, Satoko Aiba, Reiko Arai\",\"doi\":\"10.1177/13872877251361051\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We retrospectively reviewed 20 consecutive patients with Alzheimer's disease who switched from lecanemab to donanemab. No new amyloid-related imaging abnormalities (ARIA) or significant adverse events were observed during the first five donanemab infusions. Prior exposure to lecanemab may reduce ARIA risk. Cognitive function remained stable. These preliminary observations suggest that switching between anti-amyloid therapies may be safe in the short term, though larger prospective studies are warranted.\",\"PeriodicalId\":14929,\"journal\":{\"name\":\"Journal of Alzheimer's Disease\",\"volume\":\" \",\"pages\":\"13872877251361051\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Alzheimer's Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/13872877251361051\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13872877251361051","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

我们回顾性回顾了20例连续的阿尔茨海默病患者，他们从lecanemab切换到donanemab。在前5次donanemab输注期间，未观察到新的淀粉样蛋白相关影像学异常（ARIA）或显著不良事件。先前接触lecanemab可降低ARIA风险。认知功能保持稳定。这些初步观察结果表明，在抗淀粉样蛋白疗法之间的转换在短期内可能是安全的，尽管更大规模的前瞻性研究是必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease.

We retrospectively reviewed 20 consecutive patients with Alzheimer's disease who switched from lecanemab to donanemab. No new amyloid-related imaging abnormalities (ARIA) or significant adverse events were observed during the first five donanemab infusions. Prior exposure to lecanemab may reduce ARIA risk. Cognitive function remained stable. These preliminary observations suggest that switching between anti-amyloid therapies may be safe in the short term, though larger prospective studies are warranted.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Alzheimer's Disease 医学-神经科学

CiteScore

6.40

自引率

7.50%

发文量

1327

审稿时长

2 months

期刊介绍： The Journal of Alzheimer''s Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer''s disease. The journal publishes research reports, reviews, short communications, hypotheses, ethics reviews, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer''s disease.